GB1473148A - - Google Patents

Info

Publication number
GB1473148A
GB1473148A GB4017574A GB4017574A GB1473148A GB 1473148 A GB1473148 A GB 1473148A GB 4017574 A GB4017574 A GB 4017574A GB 4017574 A GB4017574 A GB 4017574A GB 1473148 A GB1473148 A GB 1473148A
Authority
GB
United Kingdom
Prior art keywords
deoxyribosyl
ribosyl
phosphates
diaquodiammineplatinum
alkylribosyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4017574A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to GB4017574A priority Critical patent/GB1473148A/en
Publication of GB1473148A publication Critical patent/GB1473148A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1473148 Platinum-containing derivatives of uracil RESEARCH CORP 16 Sept 1974 40175/74 Heading C2C The invention comprises complexes prepared by reacting at 0-55‹ C., 1 mole of cis-diaquodiammineplatinum (II) with 1-2 moles of a compound of formula or its 5,6-dihydro derivative, wherein R 1 and R 2 are each H, alkyl, dialkylamino, di(haloalkyl)- amino, halogen, OH, hydroxyalkyl or carboalkoxy, and R 3 and R 4 are each H, alkylribosyl, deoxyribosyl, ribosyl, triacetyl-, tribenzoyl- or 2<SP>1</SP>,3<SP>1</SP>-alkylideneribosyl, ribosyl phosphates or deoxyribosyl phosphates. Therapeutic compositions for treating cancer or bacterial or viral infections comprise the above complexes, and may be administered orally or parenterally.
GB4017574A 1974-09-16 1974-09-16 Expired GB1473148A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB4017574A GB1473148A (en) 1974-09-16 1974-09-16

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4017574A GB1473148A (en) 1974-09-16 1974-09-16

Publications (1)

Publication Number Publication Date
GB1473148A true GB1473148A (en) 1977-05-11

Family

ID=10413576

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4017574A Expired GB1473148A (en) 1974-09-16 1974-09-16

Country Status (1)

Country Link
GB (1) GB1473148A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
WO1996023506A1 (en) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Use of 5'substituted nucleosides to provide resistance in cytostatic treatment and medicaments containing said nucleosides
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7122528B2 (en) 2001-02-23 2006-10-17 Resprotect Gmbh Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316426B1 (en) 1987-10-28 2001-11-13 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6258795B1 (en) 1987-10-28 2001-07-10 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US6274563B1 (en) 1987-10-28 2001-08-14 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6344447B2 (en) 1987-10-28 2002-02-05 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7105498B2 (en) 1987-10-28 2006-09-12 Wellstat Therapeutics Corporation Acylated uridine and cytidine and uses thereof
US7166581B1 (en) 1987-10-28 2007-01-23 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1996023506A1 (en) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Use of 5'substituted nucleosides to provide resistance in cytostatic treatment and medicaments containing said nucleosides
US6589941B1 (en) 1995-02-01 2003-07-08 Resprotect Gmbh Utilization of 5′ substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions
US7122528B2 (en) 2001-02-23 2006-10-17 Resprotect Gmbh Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases

Similar Documents

Publication Publication Date Title
GB1132082A (en) The manufacture of pyrimidine derivatives
AU565168B2 (en) 4:-demethyl - 4 - epipodophyllotoxin derivatives
AU554227B2 (en) Vicinal dihydroxyalkylxanthine derivatives
GB1145789A (en) New n-aralkyl-adenosine derivatives
ES476109A1 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions and their preparation.
ES460040A1 (en) 4-hydroxyphenylalkanolamine derivatives and preparation thereof
ES8706654A1 (en) Benzothiazine derivatives.
NZ308398A (en) 2-amino benzoxazin-4-one derivatives and medicaments
NO922148L (en)
GB1473148A (en)
ES447011A1 (en) Anti-diarrheal compounds
GB1290818A (en)
GB1130956A (en) Substituted pteridines and pharmaceutical compositions containing them
AU571206B2 (en) 6-hydroxyalkyl-penem derivatives
GB1229082A (en)
ES8401926A1 (en) Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same.
ES8502435A1 (en) 2(1H)-pyridinones, useful as cardiotonic agents, and their production.
ES8507472A1 (en) New compounds, pharmaceutical preparations containing same and process for their preparation.
ES8404373A1 (en) Novel 2-beta-D-ribofuranosylselenazole-4-carboxamide compounds and methods for their production.
MY106512A (en) Process for the preparation of 6-(substitutedaminopro- pionyl)-derivatives of fokskolin.
GB1357733A (en) 1,2,4-oxadiazole derivatives
GB1148288A (en) A process for the manufacture of benzdiaz[1,4]epine derivatives
GB1088102A (en) Halogen substituted pyrido-pyrimidines
ES8308335A1 (en) Antiviral deoxyuridine compounds.
GB1173309A (en) The Manufacture of Benzdiaz[1,4]Epine Derivatives

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee